Amazon-backed (AMZN) Anthropic (PC:ANTPQ) has officially entered the life sciences sector with the launch of Claude for Life Sciences, which is a new tool that is designed to help researchers speed up the scientific discovery process using AI. The platform is built on Anthropic’s existing Claude models and connects with widely used lab tools to support literature reviews, hypothesis generation, data analysis, and the drafting of regulatory submissions. Notably, this is the company’s first major push into biotech and follows the hiring of industry veteran Eric Kauderer-Abrams to lead its life sciences division.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Unsurprisingly, Kauderer-Abrams said that Anthropic wants a significant share of global life sciences research to run on Claude. In addition, the company’s latest model, Claude Sonnet 4.5, is said to perform much better in life science tasks, such as understanding lab protocols. In order to make the new platform useful in real-world research settings, Anthropic built connections with platforms like Benchling and PubMed and teamed up with partners such as Deloitte, KPMG, AWS, and Google Cloud (GOOGL) to help labs start using AI in their work.
Impressively, in a demo, a scientist used Claude to compare two drug study designs. The AI pulled data from Benchling, created summaries, and helped write a full report (something that normally takes days) within minutes. Although Kauderer-Abrams stressed that AI won’t magically shorten multi-year clinical trials, it can significantly accelerate slow and expensive tasks. Therefore, Anthropic’s plan is to carefully improve each part of the discovery process where AI can make a real difference, without overpromising results.
What Is the Price Target for AMZN Stock?
Turning to Wall Street, analysts have a Strong Buy consensus rating on Amazon stock based on 44 Buys assigned in the past three months. Furthermore, the average AMZN stock price target of $267.30 per share implies 23.5% upside potential from current levels.
